Ralph J. S. van Mechelen

Ralph J. S. van Mechelen

Auto-generated profile, based on publicly available information

Ralph J. S. van Mechelen

University Eye Clinic Maastricht, Maastricht University Medical Center+ (MUMC+) Maastricht 6202 AZ The Netherlands

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2022 in Translational Vision Science & Technology
Verified
Journal Article
Open access
PDF file
RMRalph J. S. van Mechelen
Ralph J. S. van Mechelen
JWJarno E. J. Wolters
Jarno E. J. Wolters
MHMarjolein Herfs
Marjolein Herfs
CBChristian J. F. Bertens
Christian J. F. Bertens
MGMarion Gijbels
Marion Gijbels
HBHenny J. M. Beckers
Henny J. M. Beckers
Purpose: The PreserFlo MicroShunt is an innovative implant for the surgical treatment of glaucoma. Although usually effective, surgeries can still fail due to fibrosis. This study was conducted to gain insight into the histological aspects of the fibrotic response and find potential targets to reduce postoperative fibrosis. Methods: Fifteen New Zealand White rabbits were implanted with a microshunt and followed up for 40 days. Animals were euthanized at postoperative days (PODs) 1, 5, and 40 to collect eyes for histological evaluation. Bleb formation and ocular health were assessed by slit-lamp (SL) biomicroscopy and optical coherence tomography (OCT). Intraocular pressure (IOP) was measured using rebound tonometry. Results: Blebs failed after approximately 2 weeks based on bleb survival and IOP measurements. No severe complications were observed with OCT and SL. Histology revealed a wide variety of cells, in the bleb and around the microshunt, including polymorphonuclear leucocytes (PMNs), myofibroblasts, and foreign body giant cells, at different PODs. Conclusions: Implantation of a poly(styrene-b-isobutylene-b-styrene) microshunt in rabbits resulted in the occurrence of a wide variety of cells during the wound-healing response. Future research should further elucidate the potential of these (earlier often overlooked) cells to target the fibrotic response in vivo—for example, by developing novel antifibrotic drugs, methods for sustained delivery of medications, or augmenting material properties. Translational Relevance: Current antifibrotic therapies aim to inhibit myofibroblasts; however, a wide variety of cells are involved in the fibrotic response. Future research focusing on these cells could offer novel methods for reducing the fibrotic response after glaucoma surgery.

31 January 2022 in Experimental Eye Research
Verified
Journal Article
Open access
RMRalph J.S. van Mechelen
Ralph J.S. van Mechelen
JWJarno Ej. Wolters
Jarno Ej. Wolters
CBChristian J.F. Bertens
Christian J.F. Bertens
CWCarroll A.B. Webers
Carroll A.B. Webers
FBFrank J.H.M. van Den Biggelaar
Frank J.H.M. van Den Biggelaar
HBHenny J.M. Beckers
Henny J.M. Beckers
Glaucoma, a degenerative disease of the optic nerve, is the leading cause of irreversible blindness worldwide. Currently, there is no curative treatment. The only proven treatment is lowering intraocular pressure (IOP), the most important risk factor. Glaucoma filtration surgery (GFS) can effectively lower IOP. However, approximately 10% of all surgeries fail yearly due to excessive wound healing, leading to fibrosis. GFS animal models are commonly used for the development of novel treatment modalities. The aim of the present review was to provide an overview of available animal models and anti-fibrotic drug candidates. MEDLINE and Embase were systematically searched. Manuscripts until September 1st, 2021 were included. Studies that used animal models of GFS were included in this review. Additionally, the snowball method was used to identify other publications which had not been identified through the systematic search. Two hundred articles were included in this manuscript. Small rodents (e.g. mice and rats) are often used to study the fibrotic response after GFS and to test drug candidates. Due to their larger eyes, rabbits are better suited to develop medical devices. Novel drugs aim to inhibit specific pathways, e.g. through the use of modulators, monoclonal antibodies, aqueous suppressants or gene therapy. Although most newly studied drugs offer a higher safety profile compared to antimetabolites, their efficacy is in most cases lower when compared to MMC. Current literature on animal models and potential drug candidates for GFS were summarized in this review. Future research should focus on refining current animal models (for example through the induction of glaucoma prior to undertaking GFS) and standardizing animal research to ensure a higher reproducibility and reliability across different research groups. Lastly, novel therapies need to be further optimized, e.g. by conducting more research on the dosage, administration route, application frequency, the option of creating combination therapies, or the development of drug delivery systems for sustained release of anti-fibrotic medication.

13 June 2023 in Macromolecular Bioscience
Verified
Journal Article
Open access
RMRalph J.S. van Mechelen
Ralph J.S. van Mechelen
JWJarno E.J. Wolters
Jarno E.J. Wolters
SFSebastian Fredrich
Sebastian Fredrich
CBChristian J.F. Bertens
Christian J.F. Bertens
MGMarion J.J. Gijbels
Marion J.J. Gijbels
HBHenny J.M. Beckers
Henny J.M. Beckers
Fibrosis of the filtering bleb is one of the main causes of failure after bleb‐forming glaucoma surgery. Intraoperative application of mitomycin C (MMC) is the current gold standard to reduce the fibrotic response. However, MMC is cytotoxic and one‐time application is often insufficient. A sustained‐release drug delivery system (DDS), loaded with MMC, may be less cytotoxic and equally or more effective. Two degradable (polycaprolactone (PCL) and polylactic‐co‐glycolic acid (PLGA)) MMC‐loaded DDSs are developed. Release kinetics are first assessed in vitro followed by rabbit implants in conjunction with the PRESERFLO MicroShunt. As a control, the MicroShunt is implanted with adjunctive use of a MMC solution. Rabbits are euthanized at postoperative day (POD) 28 and 90. The PLGA and PCL DDSs release (on average) 99% and 75% of MMC, respectively. All groups show functioning blebs until POD 90. Rabbits implanted with a DDS show more inflammation with avascular thin‐walled blebs when compared to the control. However, collagen is more loosely arranged. The PLGA DDS shows less inflammation, less foreign body response (FBR), and more complete degradation at POD 90 when compared to the PCL DDS. Further optimization with regard to dosage is required to reduce side effects to the conjunctiva.

18 September 2019 in Diagnostics
Verified
Journal Article
Open access
PDF file
MBMelinda Barkhuizen
Melinda Barkhuizen
JVJohan S.H. Vles
Johan S.H. Vles
RMRalph van Mechelen
Ralph van Mechelen
MVMarijne Vermeer
Marijne Vermeer
BKBoris W. Kramer
Boris W. Kramer
DGDanilo AW Gavilanes
Danilo AW Gavilanes
Somatosensory evoked potentials (SSEPs) are a valuable tool to assess functional integrity of the somatosensory pathways and for the prediction of sensorimotor outcome in perinatal injuries, such as perinatal hypoxia-ischemia (HI). In the present research, we studied the translational potential of SSEPs together with sensory function in the male adult rat with perinatal HI compared to the male healthy adult rat. Both somatosensory response and evoked potential were measured at 10-11 months after global perinatal HI. Clear evoked potentials were obtained, but there were no group differences in the amplitude or latency of the evoked potentials of the preceding sensory response. The bilateral tactile stimulation test was also normal in both groups. This lack of effect may be ascribed to the late age-of-testing and functional recovery of the rats.

27 April 2023 in Advanced Biology
Verified
Journal Article
Open access
RMRalph J. S. van Mechelen
Ralph J. S. van Mechelen
PSPhani Sudarsanam
Phani Sudarsanam
CBChristian J. F. Bertens
Christian J. F. Bertens
MTMehmet O. Tas
Mehmet O. Tas
MGMarion J. J. Gijbels
Marion J. J. Gijbels
HBHenny J. M. Beckers
Henny J. M. Beckers
Lowering intraocular pressure (IOP) by placement of a glaucoma shunt is an effective treatment for glaucoma. However, fibrosis of the outflow site can hamper surgical outcome. In this study, the antifibrotic effect of adding an endplate (with or without microstructured surface topographies) to a microshunt made of poly(styrene‐block‐isobutylene‐block‐styrene) is investigated. New Zealand white rabbits are implanted with a control implant (without endplate) and modified implants. Afterward, bleb morphology and IOP is recorded for 30 days. After killing of the animals, eyes are collected for histology, Addition of an endplate extended bleb survival, Topography‐990 has the longest recorded bleb‐survival time. Histology reveals that the addition of an endplate increases the presence of myofibroblasts, macrophages, polymorphonuclear cells, and foreign body giant cells compared to the control. However, an increased capsule thickness and inflammatory response are observed in the groups with surface topographies, The addition of an endplate results in prolonged bleb survival, demonstrating that engineering of the shape of glaucoma implants could prolong bleb functionality. Future research should further elaborate the effect of surface topographies on long‐term bleb survival, since an increased presence of pro‐fibrotic cells and increased capsule thickness are observed compared to the control.